Liver international : official journal of the International Association for the Study of the Liver 2017 12 14() doi 10.1111/liv.13665
Among HIV-positive individuals, seroprotection for hepatitis A virus (HAV) following primary vaccination may wane with time. However, seroresponses to HAV revaccination are rarely investigated among HIV-positive patients who have lost protective antibodies after primary vaccination.
During the outbreak of acute hepatitis A in Taiwan after June 2015, HAV-seronegative, HIV-positive individuals were advised to receive 2 doses of HAV vaccines at 24 weeks apart. A retrospective 1:2 matched case-control study was conducted to compare the seroresponses at weeks 4, 24, 28 and 48 of HAV vaccination between those who underwent revaccination after having lost protective antibodies (case patients) and those who underwent primary vaccination (controls).
Seventy-five case patients and 150 matched controls were included. The serological response rates were consistently higher among the case patients than controls: 88.1% versus 10.5% at week 4 following the first dose of HAV vaccination (p<0.001); 93.3% versus 46.0% at week 24 (immediately before the second dose) (p<0.001); 98.7% versus 62.7% at week 28 (4 weeks after the second dose) (p<0.001); and 98.7% versus 92.7% at week 48 (p=0.06). The anti-HAV antibody titers as reflected by the semi-quantitative assay for the case patients were also significantly higher than the controls at weeks 24, 28, and 48 following HAV vaccination. CONCLUSIONS
We demonstrated faster and better serological responses to HAV revaccination among the HIV-positive individuals who had lost their anti-HAV antibodies after primary vaccination. Single dose of HAV revaccination may provide rapid and sufficient seroresponses for HAV during the outbreak of acute hepatitis A. This article is protected by copyright. All rights reserved.